艾塞利斯制药

最新新闻

• 公司公告
  Exelixis | 4: Statement of changes in beneficial ownership of securities-Officer Haley Patrick J.
  SEC · 2026/5/20
• 评级变动
  Truist Financial Downgrades Exelixis(EXEL.US) to Hold Rating, Raises Target Price to $54
  \u5e02\u573a\u8d44\u8baf · 2026/6/25
• BofA Securities Maintains Exelixis(EXEL.US) With Sell Rating, Maintains Target Price $41
  \u5e02\u573a\u8d44\u8baf · 2026/10/9
• 评级变动
  Stifel Maintains Exelixis(EXEL.US) With Hold Rating, Announces Target Price $47
  \u5e02\u573a\u8d44\u8baf · 2026/5/7
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Caris Life Sciences, Inc. (CAI) and Exelixis (EXEL)
  TipRanks · 2026/7/2
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), Kiora Pharmaceuticals (KPRX) and MAIA Biotechnology, Inc. (MAIA)
  TipRanks · 2026/6/22
• 公司公告
  Exelixis | 4: Statement of changes in beneficial ownership of securities-Director Heyman Tomas J.
  SEC · 2026/5/30
• William Blair Maintains Exelixis(EXEL.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/11
• 公司公告
  Exelixis | 4: Statement of changes in beneficial ownership of securities-Officer Haley Patrick J.
  SEC · 2026/5/23
• 公司公告
  Exelixis | 4: Statement of changes in beneficial ownership of securities-Officer Senner Christopher J.
  SEC · 2026/3/3
• Truist Financial Maintains Exelixis(EXEL.US) With Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/14
• 评级变动
  H.C. Wainwright Maintains Exelixis(EXEL.US) With Buy Rating, Maintains Target Price $56
  \u5e02\u573a\u8d44\u8baf · 2026/7/2
• Analysts Offer Insights on NA Companies: Exelixis (EXEL) and Resolution Minerals Ltd. Sponsored ADR (RML)
  TipRanks · 2026/9/14
• Stifel Maintains Exelixis(EXEL.US) With Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/13
• 评级变动
  Goldman Sachs Maintains Exelixis(EXEL.US) With Buy Rating, Maintains Target Price $64
  \u5e02\u573a\u8d44\u8baf · 2026/8/6
• 评级变动
  H.C. Wainwright Maintains Exelixis(EXEL.US) With Buy Rating, Raises Target Price to $56
  \u5e02\u573a\u8d44\u8baf · 2026/5/7
• 评级变动
  A Quick Look at Today's Ratings for Exelixis(EXEL.US), With a Forecast Between $45 to $55
  \u5e02\u573a\u8d44\u8baf · 2026/5/6
• 评级变动
  Truist Financial Maintains Exelixis(EXEL.US) With Hold Rating, Raises Target Price to $56
  \u5e02\u573a\u8d44\u8baf · 2026/7/7
• 评级变动
  Goldman Sachs Maintains Exelixis(EXEL.US) With Buy Rating, Raises Target Price to $64
  \u5e02\u573a\u8d44\u8baf · 2026/7/23
• 公司公告
  Exelixis | 4: Statement of changes in beneficial ownership of securities-Officer Senner Christopher J.
  SEC · 2026/5/20
• BofA Securities Maintains Exelixis(EXEL.US) With Sell Rating, Maintains Target Price $41
  \u5e02\u573a\u8d44\u8baf · 2026/9/13

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。